Global Medtech Companies Seeking Ways To Fortify Competitive Advantage In China
This article was originally published in PharmAsia News
Ranked only behind the U.S., China’s medtech market is set for a boom as more physicians are trained to perform common medical procedures that are still low-penetrating. Multinational manufacturers will have to fend off strong domestic firms.
You may also be interested in...
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.
Some manufacturers willing to offer global-low prices in exchange for reimbursement coverage in the world's second-largest pharma market.